Hasselbalch, Hans Carl <br/><br/>
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.  [electronic resource] 

 -  American journal of hematology  Dec 2003 
 - 238-42 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0361-8609 
<br/><br/><label>Standard No.: </label>10.1002/ajh.10431  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Benzamides<br/>Female<br/>Humans<br/>Hydroxyurea--therapeutic use<br/>Imatinib Mesylate<br/>Interferon-alpha--therapeutic use<br/>Leukocytosis--chemically induced<br/>Male<br/>Middle Aged<br/>Piperazines--administration & dosage<br/>Polycythemia--complications<br/>Primary Myelofibrosis--drug therapy<br/>Pyrimidines--administration & dosage<br/>Thrombocytosis--chemically induced<br/>Treatment Outcome